

Ref: GLL/BSE/2020/Nov-03

Date: November 12, 2020

To
Corporate Relations Manager
BSE Limited
Phiroje Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001

To
Listing Manager
The Ahmedabad Stock Exchange Limited
A-2, Kamdhenu Complex,
Opposite Sahajanand College,
120 Feet Ring Rd, Panjara Pol, Ambawadi,
Ahmedabad – 380 015

To
The Secretary
The Calcutta Stock Exchange Limited
#7, Lyons Range, Murgighata,
Dalhousie, Kolkata – 700 001

Sub: Outcome of the Board Meeting held on November 12, 2020 of Gennex Laboratories Limited

Ref: Regulation 33 & 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Ma'am,

In just concluded Meeting of the Board Directors of the Company, the board has considered and approved:

1. Unaudited (Standalone and Consolidated) Financial Statements for the Quarter and Half Year ended September 30, 2020 (annexed herewith);
2. Limited review reports from the Statutory Auditor on Unaudited (Standalone and Consolidated) Financial Statements for the Quarter and Half Year ended September 30, 2020 (annexed herewith);
3. Resignation of Mr. Vinod Choraria (DIN: 08497499) as an Independent Director of the Company.


This intimation is also uploaded in the Company website: www.gennexlab.com.

We request you to take the above information on record and acknowledge the receipt of the same.

Thanking you,

Yours Truly,

For Gennex Laboratories Limited


Rajesh Vankadara
Company Secretary &
Compliance Officer
Membership #A44949



Gennex Laboratories Limited

**GENNEX LABORATORIES LIMITED**

CIN: L24230TG1990PLC011168

Regd. Off: Survey #133, IDA Bollaram, Jinnaram Mandal, Sangareddy - 502 325, Telangana State, India
Tel. No.+91-40-67334400-30, Fax: +91-40-67334433, Email: info@gennexlab.com website: www.gennexlab.com**Unaudited Financial Results for the Quarter and Half Year ended September 30, 2020**

Statement of standalone of Unaudited Financial Results for the Quarter and Half Year ended September 30,2020

(All amounts in Rs.lakhs except EPES and Ratios)

Sl. No.	Particulars	Quarter Ended			Half Year Ended		Year ended
		30.09.2020	30.06.2020	30.09.2019	30.09.2020	30.09.2019	31.03.2020
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Income from Operations						
	(a) Revenue from Operations	1493.77	1304.63	1339.60	2798.40	2948.33	5561.73
	(b) Other operating Income	19.40	14.77	20.24	34.17	54.42	95.14
	Total Income from operations (net)	1513.17	1319.40	1359.84	2832.57	3002.75	5656.87
2	Expenses						
	(a) Cost of material consumed	908.80	652.51	832.33	1561.31	1862.40	3513.11
	(b) Purchases of stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-19.83	196.74	-62.02	176.91	-159.57	-151.11
	(d) Employee benefit expense	168.73	155.10	163.21	323.83	333.34	681.19
	(e) Finance Cost	22.78	16.02	17.65	38.80	43.07	75.36
	(f) Depreciation and amortisation expense	21.97	21.98	28.04	43.95	50.96	100.50
	(g) Other expenses	288.66	226.01	316.69	514.67	701.87	1193.82
	Total expenses	1391.11	1268.36	1295.90	2659.47	2832.07	5412.87
3	Profit(+)/Loss(-) from operations before exceptional items and tax (1-2)	122.06	51.04	63.94	173.10	170.68	244.00
4	Exceptional items	0.00	0	10.86	0.00	10.86	10.86
5	Profit(+)/Loss(-) before tax (3+4)	122.06	51.04	74.80	173.10	181.54	254.86
6	Tax Expenses for earlier years						-10.34
7	Current Tax	-35.50	-14.20	-19.00	-49.70	-46.00	-75.00
8	Deferred tax						16.12
9	Total Tax expense	-35.50	-14.20	-19.00	-49.70	-46.00	-69.22
10	Net Movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0	0	0	0	0
11	Net Profit for the period from continuing operation (5-9)	86.56	36.84	55.80	123.40	135.54	185.64
12	Profit(+)/Loss(-) from discontinued operations before tax						
13	Tax expense of discontinued operations	0.0	0.0	0.0	0.0	0.0	0.0
14	Net Profit(loss) for the period from discontinued operations	0.0	0.0	0.0	0.0	0.0	0.0
15	Share of Profit(loss) of associates and Joint Ventures accounted for using equity method	0.0	0.0	0.0	0.0	0.0	0.0
16	Total profit(loss) for period	86.56	36.84	55.80	123.40	135.54	185.64
17	Other comprehensive Income net of taxes	0.00	0.00	0.00	0.00	0.00	0
18	Net profit(loss) for period	86.56	36.84	55.80	123.40	135.54	185.64
19	Paid-up Equity Share Capital (Face value Rs. 1 each Equity Share)	1265.03	1265.03	1265.03	1265.03	1265.03	1265.03
	Other Equity						2320.38
20	Earning Per Equity Share (EPS) (Face value of Rs 1 per Share) (of Rs. 1 each) (not annualised) :						
	(a) Basic	0.068	0.029	0.044	0.098	0.107	0.147
	(b) Diluted	0.068	0.029	0.044	0.098	0.107	0.147

Notes to the results:

- The above unaudited Financial Results have been reviewed by the Audit Committee of its meeting held on 12.11.2020 and the same were approved and taken on record by the Board of Directors at its meeting held on the same day.
- The Statutory Auditors of the Company have carried out the limited review of the above Unaudited Financial Results for the Quarter and Half Year ended September 30, 2020
- The above results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (IND-AS) prescribed u/s. 133 of the accounting practices and policies to the extent applicable Companies Act, 2013 and other recognised
- The Company operates in single segment and therefore the Segment Reporting as per AS-17 is not applicable for the Company.
- Previous period's figures have been rearranged / regrouped wherever necessary.
- The quarterly unaudited Financial Results for the Quarter and Half Year ended September 30, 2020 are available on the Company's Website i.e., www.gennexlab.com and also available on BSE website i.e., www.bseindia.com


For Gennex Laboratories Limited

T M Gopalakrishnan
T M Gopalakrishnan
Director
DIN: 03137458



Place: Hyderabad
Date: 12.11.2020

Standalone Statement of Assets and Liabilities		(Rs. in lakhs)	
Particulars	As at September 30, 2020	As at March 31, 2020	
	Unaudited	Audited	
1 Non-Current Assets			
a) Property, Plant and Equipment	1448.82	1492.76	
b) Capital Work-In-Progress	5.05	0.00	
c) Goodwill	0.00	0.00	
Financial Assets			
d) Investments in Associate	700.00	700.00	
Other Investments	1.00	1.00	
e) Loans, non-current	0.00	0.00	
f) Other non-current Financial Assets	0.00	0.00	
g) Deferred Tax Assets (Net)	0.00	0.00	
h) Other non-current Assets	22.04	22.04	
Total Non-current assets	2176.91	2215.80	
2 Current Assets			
Inventories	539.92	743.73	
Financial Assets			
a) Trade receivables, current	691.96	627.96	
b) Cash and Cash equivalents	20.13	19.37	
c) Bank Balance other than Cash and Cash equivalents	203.20	71.89	
d) Other current financial assets	1999.28	1827.42	
Total Current Financial Assets	2914.57	2546.64	
e) Current Tax Assets (Net)			
f) Other current assets	151.57	206.45	
Total Current assets	3606.06	3496.82	
Total Assets	5782.97	5712.62	
EQUITY AND LIABILITIES			
1 EQUITY			
Equity attributable to owners of parent			
a) Equity Share Capital	1265.03	1265.03	
b) Other Equity	2443.77	2320.38	
Total Equity	3708.80	3585.41	
LIABILITIES			
Non-current liabilities			
Financial Liabilities:			
a) Borrowings	0.00	0.00	
b) Other financial liabilities	0.00	0.00	
Total Non Current Financial Liabilities	0.00	0.00	
Other Non Current Financial Liabilities:			
a) Deferred Tax Liabilities (Net)	39.89	39.89	
b) Deferred Government Grants, Non- Current	1.55	1.55	
Total Non-current liabilities	41.44	41.44	
Current Liabilities			
Financial Liabilities:			
a) Borrowings	648.28	498.43	
b) Trade payables			
Total outstanding dues of Micro Enterprises and small enter	83.22	120.04	
Total outstanding dues of creditors other than micro enter	744.46	693.16	
c) Other Financial Liabilities	346.37	532.52	
Total Current Financial Liabilities	1822.33	1844.15	
Other Current Liabilities			
d) Provisions, Current	28.14	28.14	
e) Current Tax Liabilities (Net)	182.26	213.48	
f) Deferred Government Grants, Current	0.00	0.00	
Total Current liabilities	210.40	241.62	
Total Liabilities	2074.17	2127.21	
Total Equity And Liabilities	5782.97	5712.62	



M. S. S. S.


GENNEX LABORATORIES LIMITED

Standalone Cash Flow Statement

Particulars	30-09-2020 (Rs. In Lacs)	31-03-2020 (Rs. In Lacs)
A. CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit before Tax	173.10	254.86
Adjustment for :		
Depreciation and amoratisation expense	43.95	100.50
Finance Cost	38.80	75.36
Interest Income	-2.73	-7.93
(Gain)/loss on sale of asset	0.00	0.00
Operating Profit before working capital changes	253.11	422.79
Adjustment for :		
Trade payables and other liability	-171.67	226.23
Trade receivables	-64.00	411.82
Inventories	203.81	-211.02
Financial and other Assets	-116.98	-1016.54
Cash generated from operations	104.27	-166.72
Adjustments for :		
Income Taxes paid	-80.92	-0.41
Net Cash from operating activities	23.34	-167.13
B. CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of property,plant and equipment	-5.05	-29.45
Sale of property,plant and equipment	0.00	0.00
Interest Income	2.73	7.93
Net Cash used in Investing activities	-2.32	-21.52
C. CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from Borrowings	0.00	0.00
Changes in Long Term Borrowings	0.00	-3.94
Changes in Short Term Borrowings (Net)	149.85	44.56
Interest Paid	-38.80	-75.36
Net Cash from Financing activities	111.05	-34.74
Net Increase / (Decrease) in Cash and Cash equivalent (A+B+C)	132.08	-223.39
Cash and Cash Equivalents as at the beginning of the year	91.26	314.65
Cash and Cash Equivalents as at the end of the period	223.34	91.26

Notes:

1. The above Cash Flow Statement has been prepared under the " Indirect Method" set out in Indian Accounting Standard (Ind-AS)- 7 on Statement of Cash Flow.
2. Figures in bracket indicate cash outflow.
3. Previous year comparatives have been reclassified to confirm with current year's presentation, wherever applicable.



**GENNEX LABORATORIES LIMITED**

CIN: L24230TG1990PLC011168

Regd. Off: Survey #133, IDA Bollaram, Jinnaram Mandal, Sangareddy - 502 325, Telangana State, India
Tel. No.+91-40-67334400-30, Fax: +91-40-67334433, Email: info@gennexlab.com website: www.gennexlab.com

Unaudited Financial Results for the Quarter and Half Year ended September 30, 2020

Statement of Consolidated Unaudited Financial Results for the Quarter and Half Year ended September 30, 2020 (All amounts in Rs.lakhs except EPES and Ratios)

Sl. No.	Particulars	Quarter Ended			Half Year Ended		Year ended
		30.09.2020	30.06.2020	30.09.2019	30.09.2020	30.09.2019	31.03.2020
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Income from Operations						
	(a) Revenue from Operations	1493.77	1304.63	1339.60	2798.40	2948.33	5561.73
	(b) Other operating Income	19.40	14.77	20.24	34.17	54.42	95.14
	Total Income from operations (net)	1513.17	1319.40	1359.84	2832.57	3002.75	5656.87
2	Expenses						
	(a) Cost of material consumed	908.80	652.51	832.33	1561.31	1862.40	3513.11
	(b) Purchases of stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-19.83	196.74	-62.02	176.91	-159.57	-151.11
	(d) Employee benefit expense	168.73	155.10	163.21	323.83	333.34	681.19
	(e) Finance Cost	22.78	16.02	17.65	38.80	43.07	75.36
	(f) Depreciation and amortisation expense	21.97	21.98	28.04	43.95	50.96	100.50
	(g) Other expenses	288.66	226.01	316.69	514.67	701.87	1193.82
	Total expenses	1391.11	1268.36	1295.90	2659.47	2832.07	5412.87
3	Profit(+)/Loss(-) from operations before exceptional items and tax (1-2)	122.06	51.04	63.94	173.10	170.68	244.00
4	Exceptional items	0.00	0	10.86	0.00	10.86	10.86
5	Profit(+)/Loss(-) before tax (3+4)	122.06	51.04	74.80	173.10	181.54	254.86
6	Tax Expenses for earlier years						-10.34
7	Current Tax	-35.50	-14.20	-19.00	-49.70	-46.00	-75.00
8	Deferred tax						16.12
9	Total Tax expense	-35.50	-14.20	-19.00	-49.70	-46.00	-69.22
10	Net Movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0	0	0	0	0
11	Net Profit for the period from continuing operation (5-9)	86.56	36.84	55.80	123.40	135.54	185.64
12	Profit(+)/Loss(-) from discontinued operations before tax						
13	Tax expense of discontinued operations	0.0	0.0	0.0	0.0	0.0	0.0
14	Net Profit(loss) for the period from discontinued operations	0.0	0.0	0.0	0.0	0.0	0.0
15	Share of Profit(loss) of associates and Joint Ventures accounted for using equity method	0.0	0.0	0.0	0.0	0.0	0.0
16	Total profit(loss) for period	86.56	36.84	55.80	123.40	135.54	185.64
17	Other comprehensive Income net of taxes	0.00	0.00	0.00	0.00	0.00	0
18	Net profit(loss) for period	86.56	36.84	55.80	123.40	135.54	185.64
19	Paid-up Equity Share Capital (Face value Rs. 1 each Equity Share) Other Equity	1265.03	1265.03	1265.03	1265.03	1265.03	1265.03 2320.38
20	Earning Per Equity Share (EPS) (Face value of Rs 1 per Share) (of Rs. 1 each) (not annualised) :						
	(a) Basic	0.068	0.029	0.044	0.098	0.107	0.147
	(b) Diluted	0.068	0.029	0.044	0.098	0.107	0.147

Notes to the results:

- The above unaudited Consolidated Financial Results have been reviewed by the Audit Committee of its meeting held on 12.11.2020 and the same were approved and taken on record by the Board of Directors at its meeting held on the same day.
- The Statutory Auditors of the Company have carried out the limited review of the above Unaudited Financial Results for the Quarter and Half Year ended September 30, 2020.
- The above results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (IND-AS) prescribed u/s. 133 of the accounting practices and policies to the extent applicable Companies Act, 2013 and other recognised
- The Company operates in single segment and therefore the Segment Reporting as per AS-17 is not applicable for the Company.
- Previous period's figures have been rearranged / regrouped wherever necessary.
- The quarterly unaudited Financial Results for the Quarter and Half Year ended September 30, 2020 are available on the Company's Website i.e., www.gennexlab.com and also available on BSE website i.e., www.bseindia.com

For GenNex Laboratories Limited

T M Gopalakrishnan

Director


DIN: 03137458



Place: Hyderabad

Date: 12.11.2020

Consolidated Statement of Assets and Liabilities		(Rs. in lakhs)	
Particulars	As at September 30,2020	As at March 31,2020	
	Unaudited	Audited	
1 Non-Current Assets			
a) Property, Plant and Equipment	1448.82	1492.76	
b) Capital Work-In-Progress	5.05	0.00	
c) Goodwill	0.00	0.00	
Financial Assets			
d) Investments in Associate	700.00	700.00	
Other Investments	1.00	1.00	
e) Loans,non-current	0.00	0.00	
f) Other non-current Financial Assets	0.00	0.00	
g) Deferred Tax Assets (Net)	0.00	0.00	
h) Other non-current Assets	22.04	22.04	
Total Non-current assets	2176.91	2215.80	
2 Current Assets			
Inventories	539.92	743.73	
Financial Assets			
a) Trade receivables, current	691.96	627.96	
b) Cash and Cash equivalents	20.13	19.37	
c) Bank Balance other than Cash and Cash equivalents	203.20	71.89	
d) Other current financial assets	1999.28	1827.42	
Total Current Financial Assets	2914.57	2546.64	
e) Current Tax Assets (Net)			
f) Other current assets	151.57	206.45	
Total Current assets	3606.06	3496.82	
Total Assets	5782.97	5712.62	
EQUITY AND LIABILITIES			
1 EQUITY			
Equity attributable to owners of parent			
a) Equity Share Capital	1265.03	1265.03	
b) Other Equity	2443.77	2320.38	
Total Equity	3708.80	3585.41	
LIABILITIES			
Non- current liabilities			
Financial Liabilities:			
a) Borrowings	0.00	0.00	
b) Other financial liabilities	0.00	0.00	
Total Non Current Financial Liabilities	0.00	0.00	
Other Non Current Financial Liabilities:			
a) Deffered Tax Liabilities (Net)	39.89	39.89	
b) Deffered Government Grants,Non- Current	1.55	1.55	
Total Non-current liabilities	41.44	41.44	
Current Liabilities			
Financial Liabilities:			
a) Borrowings	648.28	498.43	
b) Trade payables			
Total outstanding dues of Micro and small enterprises	83.22	120.04	
Total outstanding dues of creditors other than micro and small enterprises	744.46	693.16	
c) Other Financial Liabilities	346.37	532.52	
Total Current Financial Liabilities	1822.33	1844.15	
Other Current Liabilities			
d) Provisions, Current	28.14	28.14	
e) Current Tax Liabilities (Net)	182.26	213.48	
f) Deffered Government Grants, Current	0.00	0.00	
Total Current liabilities	210.40	241.62	
Total Liabilities	2074.17	2127.21	
Total Equity And Liabilities	5782.97	5712.62	



GENNEX LABORATORIES LIMITED

Consolidated Cash Flow Statement

Particulars	30-09-2020 (Rs. In Lacs)	31-03-2020 (Rs. In Lacs)
A. CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit before Tax	173.10	254.86
Adjustment for :		
Depreciation and amoratisation expense	43.95	100.50
Finance Cost	38.80	75.36
Interest Income	-2.73	-7.93
(Gain)/loss on sale of asset	0.00	0.00
Operating Profit before working capital changes	253.11	422.79
Adjustment for :		
Trade payables and other liability	-171.67	226.23
Trade receivables	-64.00	411.82
Inventories	203.81	-211.02
Financial and other Assets	-116.98	-1016.54
Cash generated from operations	104.27	-166.72
Adjustments for :		
Income Taxes paid	-80.92	-0.41
Net Cash from operating activities	23.34	-167.13
B. CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of property,plant and equipment	-5.05	-29.45
Sale of property,plant and equipment	0.00	0.00
Interest Income	2.73	7.93
Net Cash used in Investing activities	-2.32	-21.52
C. CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from Borrowings	0.00	0.00
Changes in Long Term Borrowings	0.00	-3.94
Changes in Short Term Borrowings (Net)	149.85	44.56
Interest Paid	-38.80	-75.36
Net Cash from Financing activities	111.05	-34.74
Net Increase / (Decrease) in Cash and Cash equivalent (A+B+C)	132.08	-223.39
Cash and Cash Equivalent as at the beginning of the year	91.26	314.65
Cash and Cash Equivalent as at the end of the period	223.34	91.26

Notes:

1. The above Cash Flow Statement has been prepared under the " Indirect Method" set out in Indian Accounting Standard (Ind-AS)- 7 on Statement of Cash Flow.
2. Figures in bracket indicate cash outflow.
3. Previous year comparatives have been reclassified to confirm with current year's presentation, wherever applicable.



Independent Auditor's Limited Review Report on Standalone Unaudited Quarterly and Year to Date Results Financial Results of Gennex Laboratories Limited pursuant to the Regulation 33 of the SEBI (listing Obligations and Disclosure Requirements) Regulation, 2015 as amended

To
**The Board of Directors,
GENNEX LABORATORIES LIMITED
Hyderabad**

We have reviewed the accompanying statement of unaudited standalone financial results of **Gennex Laboratories Limited** for the quarter and half year ended September 30, 2020, being submitted by the Company pursuant to the requirement of Regulation 33 of SEBI (LODR) Regulations, 2015 as amended. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. The statement has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' prescribed under Section 133 of the Companies Act 2013, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement, insofar as it relates to the amounts and disclosures for the quarter and half year ended September 30, 2020, in accordance with the Standard on Review Engagements (SRE) 2410 on "Review of Interim Financial Information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review if substantially less in scope than an audit conducted in accordance with Standard on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards (Ind AS) specified under Section 133 of the Companies Act, 2013 as amended read with rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad
Date: November 12, 2020
UDIN: 20205140AAAAJE7321



For PPKG & Co.
Chartered Accountants
Firm Registration Number. 009655S

Giridhari Lal Toshniwal
CA Giridhari Lal Toshniwal
(Partner)
Membership No. 205140

Independent Auditor's Review Report on Consolidated unaudited quarterly and year to date financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
**The Board of Directors,
GENNEX LABORATORIES LIMITED
Hyderabad**

We have reviewed the accompanying Statement of unaudited Consolidated Financial Results of **Gennex Laboratories Limited** ("the Parent") and its subsidiaries & Associates (the Parent and its subsidiaries & Associates together referred to as "the Group") and its share of the net profit/(loss) after tax and total comprehensive income / loss of its associates and joint ventures for the quarter and half year ended **September 30, 2020**, and for the period from April 01, 2020 to September 30, 2020 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Attention is drawn to the fact that the consolidated figures for the corresponding quarter and half year ended September 30, 2020, as reported in these financial results have been approved by the Parent's Board of Directors, but have not been subjected to review.

This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been compiled from the related consolidated financial statements which has been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013, read with the Companies (Indian Accounting Standards) Rules, 2015, as amended ("Ind AS"), and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Statement includes the results of the following entities:

Deccan Remedies Limited;

Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the branch auditors and other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



The accompanying unaudited consolidated financial results includes unaudited interim financial results and other unaudited financial information in respect of 1 Associate, which have been reviewed by their^s auditors, whose interim financial results excluding consolidation eliminations reflect total revenues of Rs. 0.00 lakhs, total net Profit after tax of Rs. 0.00 lakhs and total comprehensive Profit of Rs. 0.00 lakhs, for the quarter and half year ended September 30, 2020 as considered in the unaudited consolidated financial results. These unaudited financial results and other unaudited financial information have been approved and furnished to us by the management. Our conclusion, in so far as it relates to the affairs of these Associates, is based solely on such unaudited financial results and other unaudited financial information. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group. Our conclusion on the Statement is not modified in respect of the above matter.

Place: Hyderabad
Date: November 12, 2020
UDIN: 20205140AAAJF2943

For PPKG & Co.
Chartered Accountants
Firm Registration Number. 009655S

Giridhari Lal Toshniwal
CA Giridhari Lal Toshniwal
(Partner)
Membership No. 205140

